Kainos Medicine is a global new company that specializes in research and development of innovative medicines for brain diseases, cancers, and infectious disease. Their product pipeline includes KM-819, which is under phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under phase II clinical study to treat HIV/AIDS.
Find out more companies
Related products
-
-
-
VentureMedigen Human Care
T cell immunotherapies for solid tumors, vaccine safety and natural immunity
-
-
VentureAprogen
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid